Attending ATS 2026?
Don't go in blind. Get our curated networking cheatsheet with party lists & investor maps.
Join 5,000+ Life Science Leaders
Official Registration
Visit Official Website ↗Strategic Context
ATS 2026 is where discovery meets practice, offering pioneering clinical trials, hands-on skills-based courses, and in-depth overviews of the latest guidelines and clinical practices. Attendees can also interact directly with recognized leaders in pulmonary disease, critical illness, and sleep disorders.
Who Attends
Pulmonologists, Critical Care Physicians, Sleep Specialists, Researchers, Clinicians, Healthcare Professionals, Fellows, Residents, Students
Accommodation for ATS 2026 typically sells out 3–4 months in advance. We recommend booking hotels near the venue immediately after registration opens.
Coverage from ATS 2026
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
ATS 2026 highlights mechanistic and multimodal approaches to obstructive sleep apnea, moving beyond CPAP to targeted therapies.
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
ATS 2026 highlights evolving lung cancer management, focusing on precision medicine and novel targeted therapies for improved patient outcomes.
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Cardiopulmonary exercise testing (CPET) continues to evolve, offering enhanced diagnostic and prognostic precision for various cardiopulmonary conditions. New applications presented at ATS 2026 highlight its utility beyond traditional indications.
Pediatric Advanced Bronchoscopy: Precision in Airway Management
Advanced diagnostic and interventional bronchoscopy in pediatric patients offers precise airway management for complex conditions, reducing morbidity.
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
Alpha-1 antitrypsin (AAT) protein extends its protective role beyond established AAT deficiency, influencing general lung health.
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
Nerandomilast, a novel anti-inflammatory agent, demonstrates efficacy in reducing exacerbation rates in patients with moderate to severe COPD.
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
AIRSUPRA® (albuterol/budesonide) demonstrated a reduction in asthma exacerbations, addressing the need for improved rescue therapy.
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant efficacy in chronic weight management, offering a new therapeutic option.
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
ATS 2026 highlights the persistent gap in objective cough assessment in respiratory diseases, hindering precise diagnosis and treatment efficacy.
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Artificial intelligence applications in pulmonary medicine, presented at ATS 2026, demonstrate utility in diagnosis, prognosis, and treatment optimization.
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
Integrating AI for lung cancer prediction into multidisciplinary team workflows demonstrates operational improvements and potential for enhanced patient stratification.
Sarcoidosis: Current Understanding of Diagnosis and Management
Sarcoidosis presents a diagnostic and therapeutic challenge. This review summarises current approaches to diagnosis, staging, and treatment strategies.
Immunological Insights Inform ILD & Transplant Outcomes
New immunological insights presented at ATS 2026 clarify mechanisms of interstitial lung disease progression and allograft rejection post-transplant.
Ventilator Management: Foundations for Bedside Implementation
Effective mechanical ventilation requires precise setup and liberation strategies. Practical foundations are essential for optimal patient outcomes.
Epithelial Dysfunction: A Unified Target in Airway Disease Management
ATS 2026 highlights epithelial dysfunction as a central mechanism in upper and lower airway inflammation, informing evolving management strategies.
ATS 2026: Ultrasound Education Advances for Clinical Practice
ATS 2026 highlights advancements in ultrasound practice and instruction, addressing variability in operator proficiency and diagnostic accuracy.
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
ATS 2026 discussions on severe asthma treatment highlight the need to integrate patient-reported outcomes beyond lung function, addressing quality of life.
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
An adaptive clinical study programme for IKT-001 in Pulmonary Arterial Hypertension (PAH) was presented at ATS 2026, detailing a novel approach to trial design.
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
Managing hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) presents diagnostic and therapeutic challenges.
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
Acute respiratory failure (ARF) presents distinct physiological phenotypes and trajectories across pediatric and adult populations, necessitating age-specific management.
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Next-generation sleep diagnostics, integrating AI, wearables, and sensors, promise to redefine the care continuum for sleep disorders, moving beyond traditional polysomnography.
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
YUTREPIA® (treprostinil) inhalation powder offers a new prostacyclin treatment option for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
ATS 2026 highlights advancements in nontuberculous mycobacteria (NTM) lung disease, focusing on improved detection, optimized therapy, and patient quality of life.
Pediatric Pulmonary Research Gaps Highlighted for Global Health
A review of pediatric pulmonary research emphasizes significant disparities in global health and underserved populations, underscoring critical unmet needs.
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
ATS 2026 highlighted epithelial cytokine pathways as a common link in severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and COPD.
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Case reports from ATS 2026 detail acute respiratory failure and immune-mediated lung disease, emphasizing ventilator and extracorporeal support.
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
BRINSUPRI® receives first approval for non-cystic fibrosis bronchiectasis (NCFB), addressing a significant unmet need in chronic respiratory care.
New Biologic Offers Option for Severe Eosinophilic Asthma
A new biologic agent presented at ATS 2026 provides an additional treatment option for patients with severe eosinophilic asthma.
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
New insights from ATS 2026 reveal significant discrepancies between patient experiences and pulmonologist perceptions in IPF and PPF management.
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
ATS 2026 session addresses persistent challenges in right heart catheterization waveform interpretation, offering a structured approach to reduce diagnostic ambiguity.
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
Advancements in Alpha-1 Antitrypsin Deficiency (AATD) focus on restoring AAT levels and achieving clinically meaningful endpoints.
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
IL-33 acts as both a pro-inflammatory cytokine and a contributor to mucus hypersecretion in COPD, complicating therapeutic targeting.
Triple Therapy Optimises COPD Outcomes at ATS 2026
ATS 2026 presentations highlight tailored triple therapy for obstructive lung disease, improving lung function and reducing exacerbations.
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
ATS 2026 will feature a hands-on guide to basic bronchoscopy, EBUS, and guided bronchoscopy, addressing the need for advanced procedural competency.
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
ATS 2026 discussions focused on the complex etiologies and management of bronchiectasis and NTM pulmonary disease, highlighting updated guideline recommendations.
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
New real-world evidence presented at ATS 2026 indicates that initiating triple therapy earlier in asthma management may improve patient outcomes.
ILD Diagnosis and Management: A Practical ATS 2026 Update
ATS 2026 provided a practical framework for interstitial lung disease (ILD) diagnosis and management, emphasising multidisciplinary team approaches and early antifibrotic initiation.